Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Journal of Cardiac Failure Année : 2024

Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study

Résumé

Background: Omecamtiv mecarbil improves outcomes in patients with heart failure and reduced ejection fraction (HFrEF). We examined the relationship between baseline troponin, change in troponin over time, and the treatment effect of omecamtiv mecarbil in patients enrolled in the Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF) trial (NCT02929329). Methods: GALACTIC-HF was a double-blind, placebo-controlled trial that randomized 8256 patients with symptomatic HFrEF to omecamtiv mecarbil or placebo. High sensitivity troponin I (cTnI) was measured serially at a core laboratory. We analyzed the relationship between both baseline cTnI and change in cTnI concentrations with clinical outcomes and the treatment effect of omecamtiv mecarbil. Results: Higher baseline cTnI concentrations were associated with a risk of adverse outcomes (hazard ratio for the primary endpoint of time to first HF event or CV death = 1.30; 95% CI 1.28, 1.33, p < 0.001 per doubling of baseline cTnI). Although the incidence of safety outcomes was higher in patients with higher baseline cTnI, there was no difference between treatment groups. Treatment with omecamtiv mecarbil led to a modest increase in cTnI that was related
Fichier sous embargo
Fichier sous embargo
Fichier sous embargo
0 0 8
Année Mois Jours
Avant la publication
jeudi 11 juillet 2024
Fichier sous embargo
0 0 8
Année Mois Jours
Avant la publication
jeudi 11 juillet 2024
Fichier sous embargo
jeudi 11 juillet 2024
Connectez-vous pour demander l'accès au fichier

Dates et versions

hal-04419929 , version 1 (26-01-2024)

Licence

Identifiants

Citer

G. Michael Felker, Scott Solomon, Marco Metra, John J.V. Mcmurray, Rafael Diaz, et al.. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study. Journal of Cardiac Failure, 2024, ⟨10.1016/j.cardfail.2023.11.021⟩. ⟨hal-04419929⟩
12 Consultations
4 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More